MDT|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q2'27 | $1.33 | - | - |
| Q1'27 | $1.40 | $1.45 | +3.4% |
| Q4'26 | $1.54 | $1.55 | +0.6% |
| Q3'26 | $1.69 | $1.36 | -19.5% |
| Q3'25 | $1.31 | $1.36 | +3.5% |
| Q2'25 | $1.23 | $1.26 | +2.5% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q2'27 | $9.6B | - | - |
| Q1'27 | $9.6B | $9.8B | +1.2% |
| Q4'26 | $9.7B | $9.8B | +0.8% |
| Q3'26 | $9.6B | $9.0B | -6.4% |
| Q3'25 | - | $9.0B | - |
| Q2'25 | - | $8.5B | - |
MDT|Monthly Returns
Market Data
MDT Stock Snapshot
- Market cap
- 119.45B
- P/E ratio
- 22.8
- Day range
- $92.73 – $94.65
- News sentiment
- 65/100 · Bullish
- Analyst target
- $104.76 (+10.7%)
- Consensus
- Buy · 36 analysts
MDT's technical picture is constructive, with trend and momentum pointing the same direction. Earnings and guidance carry more weight than macro data at this capitalisation.
Reverse DCF
What growth is priced into MDT?
At today's price, Medtronic plc needs to grow free cash flow about 4.0% a year for the next 10 years to justify its valuation at a 6.57% cost of capital. Over its actual history it has compounded free cash flow at 1.6% a year, so the market is asking for 2.4 percentage points above its own delivered rate. On that basis MDT looks priced roughly in line with its own growth record.
- Implied FCF growth
- 4.0%
- Historical FCF CAGR
- 1.6%
- Growth gap
- +2.4 pts
- Verdict
- FAIR
- Discount rate (WACC)
- 6.57%
- Beta
- 0.58
Behaviour On Record
What MDT's own history says about today's numbers
- Realized volatility (21d)
- 21.1% 61st pct
- Below its peak
- -30.3%
- vs 200-day average
- +5.2%
- Up days (1y)
- 48%
Medtronic plc is currently running 21.1% annualised volatility over the last 21 sessions. Measured against MDT's own 13 years of daily returns rather than a market-wide average, that is the 61st percentile — a little above its own norm, against a typical reading of 19.0%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.
MDT is trading -30.3% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -16.6%, and the deepest was -38.5% in 2020. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.
Price sits +5.2% from its 200-day moving average. Against every other day in its history, that gap ranks at the 61st percentile — a somewhat wider gap than its own norm. Over the past year MDT closed higher on 48% of sessions, and it is currently 2 sessions into a rising streak.
On September specifically: over 14 years of records, MDT finished the month higher 5 of 14 times, with a median return of -2.0% and an average of -1.9%. Its strongest month historically has been January at +3.1% on average, its weakest September at -1.9%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.
Overnight risk is measurable too: MDT has opened more than 2% away from the prior close in 58 of 3,268 sessions (1.8% of the time), with the largest gaps running +6.3% and -6.8%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.
Across the last 3 dated reports on file, MDT moved an average of 2.2% in the session after earnings, closing higher 3 of those 3 times, with a median move of +1.6% and a largest of +5.1%.
All figures computed from 3,269 daily closes between 2013-09-16 and 2026-09-15, split-adjusted, recomputed daily. Percentiles are against MDT's own 13-year history, not a peer group or index.
Sector Rotation
Is money rotating into or out of MDT's sector?
Medtronic plc sits in the Health Care sector, currently ranked 3rd of 11 GICS sectors by relative-strength rotation score (leading). Within its narrower Medical Devices industry group, MDT ranks 11th of 15 tracked industries, improving.
- Sector rank
- #3 of 11
- Sector state
- Leading
- Sector rotation score
- 80
- Industry rank
- #11 of 15
Analyst Rating Changes
Are analysts turning bullish or bearish on MDT?
UBS most recently reiterated its rating on Medtronic plc to Buy on Sep 3, 2026 with a price target of $110 (from $100). Over the last 90 days, coverage has run 1 upgrade against 0 downgrades, a net bullish lean.
- Latest action
- UBS — Buy
- 90-day upgrades
- 1
- 90-day downgrades
- 0
- Net rating momentum
- +1
